Skip to main content

Table 2 Microtissue maintenance and NM treatment in the singular and repeated exposure experiments over a period of 15 days

From: Hepatic toxicology following single and multiple exposure of engineered nanomaterials utilising a novel primary human 3D liver microtissue model

Single exposure

End-points investigated

Treatment 1 – 0 hr (day 0)

-

Change medium – 24 hr (day 1)

AK assay, cytokine secretion, albumin

Change medium – 72 hr (day 3)

Albumin

Change medium – 168 hr (day 7)

AK assay, cytokine secretion

Change medium – 216 hr (day 9)

Albumin

Change medium – 264 hr (day 11)

-

Change medium – 336 hr (day 14)

-

Change medium – 360 hr (day 15)

AK assay, cytokine secretion, lipid peroxidation, DNA damage, albumin

Multiple exposure

End-points investigated

Treatment 1 – 0 hr (day 0)

-

Change medium – 24 hr (day 1) – 48 hr recovery period

AK assay, cytokine secretion

Treatment 2 – 72 hr (day 3)

AK assay, cytokine secretion, albumin

Change medium – 96 hr (day 4) - 48 hr recovery period

AK assay, cytokine secretion, albumin

Treatment 3 – 144 hr (day 6)

AK assay, cytokine secretion

Change medium – 168 hr (day 7) - 48 hr recovery period

AK assay, cytokine secretion, albumin

Treatment 4 – 216 hr (day 9)

AK assay, cytokine secretion, albumin

Change medium – 240 hr (day 10) - 48 hr recovery period

AK assay, cytokine secretion, albumin

Treatment 5 – 288 hr (day 12)

-

Change medium – 312 hr (day 13)

AK assay, cytokine secretion

Change medium – 360 hr (day 15)

Lipid peroxidation, DNA damage, albumin